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We thank Dr Walker and his colleague for their kind interest in
our recent publication. Their approach to treating the remaining
popliteal aneurysm after exclusion and before bypass is a novel one.
I must presume that this technique was carried out through a
standard medial approach in which the entire aneurysm sac could
not be opened completely and the feeding vessels ligated directly.
Baum et al1 have shown that inducing complete sac thrombosis
with glues or coils is a useful technique for eliminating type II
endoleaks and halting aneurysm growth following endovascular
repair for abdominal aortic aneurysm. Similarly, with popliteal
aneurysms, if all source back-bleeding can be staunched at the time
of aneurysm repair, it may be safe to presume that further aneurysm
growth will not occur.
Although this procedure may have been successful in this
single patient in 3-week follow-up, it may not be appropriate to
declare this a complete success and “an effective technique for
improving the exclusion of popliteal aneurysms” just yet. Other
investigators have observed that, when feeding and outflow arter-
ies are not ligated or coiled directly, blood flow into the sac and
continued aneurysm growth (or bleeding, if the sac is left open)
can still occur. In addition, this type of therapy will not likely treat
symptoms from mass effect that may occur in patients with large
popliteal aneurysms. We would suggest that patients with popliteal
aneurysms who undergo this type of treatment should still be
followed clinically and with serial scans so that we might know that
this technique for eliminating sac perfusion is a durable one.
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Regarding “Regarding ‘Veterans Affairs (VA)
Cooperative Study #362’”
Recently, M.J.D. Tangelder et al, on behalf of the steering
Committee of the Dutch BOA Study, commented on VA Coop
Study #362 in a letter to the editor (J Vasc Surg 2003;38:629). We
would like to respond to their comments and recommendations.
First, the two studies are not comparable as the VA trial
evaluated a different hypothesis in an attempt to reduce the risk of
bypass occlusion. A treatment program in which both platelet
function and fibrin formation were simultaneously modified (war-
farin combined with aspirin) was evaluated in the VA trial while the
BOA study evaluated warfarin or aspirin independently.1,2 Sec-
ond,the doses of aspirin (325mg  VA and 80mg  BOA) and
warfarin (target INR 1.4 to 2.8 in the VA trial and 3.0 to 4.5 in
the BOA study) were different. Finally, the demographics of the
study populations were different: women represented 36% of the
BOA study group as compared with 1% in the VA trial, and the
vein bypasses in the VA trial were at a more distal site (12% AK, 26%
BK, 52% crural and 10% pedal) than those in the BOA study (46%
AK, 34% BK, 18% crural and 2% pedal).
The mean length of follow-up was 38 months in the VA trial as
compared with 21 months in the BOA study. The assisted primary
patency (LTA) of the bypasses at 3 years in the vein group for
patients treated with aspirin alone was similar (72% for BOA and
75% for VA). The BOA study did demonstrate a benefit (82%
patency) for warfarin treatment alone as compared with low-
dosage aspirin while in the VA trial the patency (75%) was similar in
both the warfarin plus aspirin group and the aspirin alone group.
The increased warfarin dosage in the BOA study may have ac-
counted for the benefit seen, but the lower dosage of aspirin could
also have been a factor.
For prosthetic bypasses, the aspirin-treated patients had a
somewhat similar patency (60% for BOA and 64% for VA); how-
ever, the warfarin plus aspirin-–treated group had an improved
patency of 72% in the VA trial as compared with 55% in the warfarin
alone–treated patients in the BOA study. Hence, we cannot agree
with Tangelder et al’s recomendation that “for patients with
prosthetic bypass grafts, ASA remains the best antithrombotic
treatment, worldwide,” but suggest that a combination of aspirin
and warfarin may be better than aspirin alone.
Willard Johnson, MD
VA Health Care System
Center Harbor, NH
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